^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    eciskafusp alfa (RG6279)

    i
    Other names: RG6279, PD1 IL2v, PD1-IL2v, RO7284755, RO 7284755, RG-6279, RG 6279, RO-7284755
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    PD1 inhibitor, IL-2 stimulant, IL-2R agonist
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=189, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    1year
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=256, Recruiting, Hoffmann-La Roche | Phase classification: P1a/1b --> P1 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Nov 2026
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    almost2years
    A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=348, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2027 --> Nov 2026 | Trial primary completion date: Mar 2027 --> May 2026
    Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TCF7 (Transcription Factor 7)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    almost3years
    A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=440, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2024 --> Jun 2027 | Trial primary completion date: Apr 2024 --> Mar 2027
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • TCF7 (Transcription Factor 7)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    over4years
    A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b; N=440; Recruiting; Sponsor: Hoffmann-La Roche; Not yet recruiting --> Recruiting
    Combination therapy • Enrollment open • Clinical
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)